The Manila Times

Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors

Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) ('Rakovina”), a biopharmaceutical company advancing innovative cancer ...
EurekAlert!

Human ATR-ATRIP complex structure discloses mechanisms of action and inhibition

Cryo-EM reconstructions of the human ATR–ATRIP complex show how clinical small-molecule inhibitors like VE-822 and RP-3500 bind to and inhibit ATR activity. A research team led by Prof. Gang Cai and ...
BioWorld

Rakovina makes progress on ATR inhibitor program

Rakovina Therapeutics Inc. has reported progress in its AI-driven KT-5000AI program, advancing the development of precision ATR (ataxia telangiectasia and Rad3-related) inhibitors designed to disrupt ...
WRIC

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

ATRN-119, a novel macrocyclic ATR inhibitor, continues to appear safe and well tolerated with no Dose Limiting Toxicities observed in ongoing Phase 1/2a study; preliminary signs of clinical benefit ...
ksn.com

Artios to Present Initial Phase 1 Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023

ART0380 is a highly competitive, wholly owned ATR inhibitor with broad clinical application alone or in combination for DDR deficient and high replication stress tumors Phase 1 dose escalation data ...
Nasdaq

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

BRANFORD, Conn.--(BUSINESS WIRE)-- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced ...